Scientists Advancing Affordable Medicines, Inc. is a nonprofit 501(c)(6) organization that seeks to provide a dedicated platform for scientists to share cutting-edge research that facilitates the development of high-quality, affordable medicines, thereby improving their accessibility to patients. Because we are sharing approaches now for the affordable medicines of tomorrow, we have adopted the tradename SAAMnow.
"Cutting Edge Approaches for Demonstrating Bioequivalence" Event Update
After careful review of the dynamic nature of the COVID‑19 situation and in consultation with other stakeholders, we have made the determination that this conference will be held in the first half of 2021. The event will likely be at the same venue, Hilton Washington DC/Rockville Executive Meeting Center, as originally planned, and we hope by that time the event participants/attendees will have the flexibility to travel and meet in-person again.
The format of our events, which typically provide ample time for panel discussion with experts, and robust debate among the attendees is best served in a live, in-person forum. The SAAMnow Board is working towards making this happen, to maximize your experiences, while doing so in a safe environment. We will continue to update you every quarter as new details become available.
SAAMnow offers individuals the opportunity to potentially impact the availability of affordable medicines through cutting-edge research. SAAMnow is looking for individuals involved/interested in research & development, formulation/manufacturing science, analytical chemistry, clinical science, statistics, quality systems, regulatory science, marketing, and allied disciplines associated with the development, manufacturing, testing, and commercialization of high quality affordable medicines. Affordable medicines are broadly defined as those that take advantage of abbreviated regulatory filing pathways, resulting in development cost savings that can then be passed on to patients. Examples include conventional generic pharmaceuticals, biosimilars, and products filed via hybrid regulatory pathways, such as the 505(b)(2) route.